Abstract 444P
Background
Cancer care in French Polynesia has been deprioritized during severe acute respiratory syndrome coronavirus 2 (SARS CoV2) pandemic due to the urgent necessity to reorganize health care systems to fight this crisis and patients (pts) were more reluctant to visit medical doctors, fearful about exposure to the virus or not wanting to disturb a saturated health system.
Methods
We aimed to assess the incidence of cancer diagnosis and cancer care during the Covid-19 period compared to the same period in 2019 (before covid) and in 2021 (after covid). We retrospectively collected data from January 2019 to Sept 2021 regarding pts visits, treatments (ttt) administrations in oncology and radiotherapy outpatient wards, at the Taaone university hospital center of French Polynesia.
Results
Regarding the newly diagnosed pts, we observed a decreased of 13.6% on oncology visits from January to Sept 2020 compared to the same period in 2019 and an increase of oncology visits after the first wave with +14.2%, from January to Sept 2021 compared to 2020. We did not observe any major impact of the crisis on ttt administrations in oncology outpatients. There was a +1.3% of activity from January to Sept 2020 compared to 2019 and a +1.5% from January to Sept 2021 compare to 2020. Regarding the radiotherapy activity, the newly diagnosed pts visits increased of +2.5% from January to Sept 2020 compared to the same period in 2019 and +21% from January to Sept 2021 compared to the same period in 2020. The ttts in radiotherapy outpatient wards decreased of -11% in 2020 (from January to Sept 2020 compared to 2019) and increased of +11% in 2021.
Conclusions
The covid 19 crisis had an impact in French Polynesia on the oncology and radiotherapy visit of the newly diagnosed patients, with more patients diagnosed after covid; while ttt administrations in oncology and radiotherapy stayed stable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06